JOURNAL ARTICLE

AstraZeneca Sees Further Growth, Lifted by Cancer Drugs.

  • Published In: Bloomberg.com, 2026. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Furlong, Ashleigh 3 of 3

Abstract

The article focuses on AstraZeneca Plc's expectations for profit growth in 2026, primarily driven by sales of cancer drugs while managing the impact of a patent expiry on its diabetes medication, Farxiga. The UK-based pharmaceutical company anticipates a low double-digit percentage increase in earnings per share and mid-to-high single-digit revenue growth. Under CEO Pascal Soriot, AstraZeneca is enhancing its pipeline of weight-loss medications, including a significant deal with CSPC Pharmaceutical Group Ltd. to access innovative dosing technology. The company aims to improve patient compliance with its obesity treatments and believes it can navigate potential impacts from US drug pricing agreements. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2026/02, pN.PAG
  • Document Type:Article
  • Subject Area:Business and Management
  • Publication Date:2026
  • Accession Number:191488714
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.